Merck has initiated efforts to broaden access to its new HIV prevention medication by authorizing companies in Africa and India to manufacture generic versions of the drug. These partnerships are expected to lower costs significantly, with projections suggesting the treatment could be available for as little as $5 per person per year.
While these agreements aim to facilitate widespread distribution in key regions, the availability of the medication and other related products remains uncertain across much of Latin America. The initiative marks a significant step in global efforts to provide affordable HIV prevention options to high-need populations.
In-depth summary · AI, neutral